Business
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million
About this update from Sangamo Therapeutics, Inc.
[{"type":"text","content":"\nAnnounced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales.\n\nAnnounced derisking milestones in pathway to anticipated biologics license application (BLA) submission for isaralgagene civaparvovec in Fabry disease, including all patients having passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway, and productive Type B Chemistry, Manufacturing and Controls (CMC) meeting with FDA.\n\nAnnounced participation at 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, including platform presentation in prestigious Presidential Symposium to showcase nonclinical proof of concept in prion disease.\n\nAnnounced pricing of $23 million underwritten registered direct equity offering.\n\n RICHMOND, Calif.--(BUSINESS WIRE)--\nSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results.\n\n“This quarter we continued to advance our promising neurology genomic medicine pipeline and are pleased to have signed our third STAC-BBB license agreement, reinforcing that Sangamo is a collaborator of choice for neurotropic capsids,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We achieved significant clinical and regulatory derisking milestones in our Fabry disease program and raised additional capital through business development and other means, to provide additional runway to secure a potential Fabry partner. With our neuropathic pain program ready to enter the clinic, we look forward to dosing the first patients with our epigenetic regulation technology, which we hope will usher in a new era in chronic pain treatment.”\n\nRecent Business Highlights\n\nCorporate Updates\n\n\nAnnounced in April a capsid license agreement with Eli Lilly and Company (Lilly) to deliver genomic medicines for diseases of the CNS. Agreement grants Lilly a worldwide exclusive license to Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, for up to five potential disease...